sFlt-1 Levels as an Indicator of the Effectiveness of Antihypertensive Agents in Gestational Hypertension

Vollständiger Abstract

Worum geht es in dieser Arbeit?

Gestational hypertension is reported to increase maternal morbidity and mortality, linked to higher levels of soluble fms-like tyrosine kinase-1 (sFlt-1) that lead to endothelial dysfunction. Methyldopa and nifedipine are thought to improve the angiogenic profile, but there are limited data on the effect on the sFlt-1 levels. Therefore, this study aimed to evaluate how methyldopa alone and the combination of methyldopa with nifedipine affect sFlt-1 levels and mean arterial pressure (MAP) in cases of gestational hypertension. This prospective observational study included 30 patients with gestational hypertension who were divided into the methyldopa monotherapy (n=15) and methyldopa-nifedipine combination group (n=15). sFlt-1 levels were calculated utilizing the enzyme-linked immunosorbent assay (ELISA) method in the first 24 hours of hospitalization (prepartum) and 24 hours after delivery (postpartum). The results showed that the combination group experienced a decrease in sFlt-1 levels and MAP by 23.8% (p<0.05) and 13.1% (p<0.001), respectively. These values were greater than those of the monotherapy group, which only reduced sFlt-1 levels by 18.8% (p>0.05) and MAP by 10.4% (p<0.05). A more consistent decrease in sFlt-1 levels was observed in five patients with severe preeclampsia who received additional magnesium sulphate (MgSO₄). In conclusion, methyldopa monotherapy and the combination of methyldopa-nifedipine reduced sFlt-1 and MAP levels. This result made sFlt-1 levels a marker of the effectiveness of antihypertensive therapy in gestational hypertension.